Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 226 Next >>

Filter Applied: adverse drug reaction (Click to remove)

A 54-year-old woman with Dementia, Myoclonus, and Ataxia
Neurol 89:e7-e12, Ali, F.,et al, 2017

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019

Muscular Dystrophies
Lancet 394:2025-2038, Mercuri, E.,et al, 2019

A young woman with symmetric weakness and behavioral disturbance
Neurol 90:e1442-e1447, Rosenberg, J.,et al, 2018

Clinicopathologic Conference, Digitalis Toxicity
NEJM 378:1931-1938, Case 15-2018, 2018

Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018

Clinicopathologic Conference, Copper Deficiency Myelopathy
NEJM 377:1977-1984, Case 35-2017, 2017

Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016

Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016

Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014

ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014

The Acquired Metabolic Disorders of the Nervous System, Hyperglycemia
Adams & Victors Principles of Neurology Chp 40, pg 1141, Ropper, A.H.,et al, 2014

The Spectrum of Statin Myopathy
Curr Opin Rheumatol 25:747-752, Mohassel, P. & Mammen, A.L., 2013

Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013

Clinicopathologic Conference,Necrotizing Noninflammatory Myopathy Consistent with Exposure to Statins
NEJM 36:944-954, Case 7-2012, 2012

Progressive Weakness with Respiratory Failure in a Patient with Sarcoidosis
Arch Neurol 69:534-537, Chaudhry,P.,et al, 2012

Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012

Neuromuscular Symptoms and Elevated Creatine Kinase After Statin Withdrawal
NEJM 362:564-565, Echaniz-Laguna,A.,et al, 2010

Hypokalemia
eMedicine Sept, Verive,M.J., 2009

Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008

Severe Botulism After Focal Injection of Botulinum Toxin
Neurol 67:1855-1856, Souayah,N.,et al, 2006

Tetraparesis Associated with Colchicine is Probably Due to Inhibition by Verapamil of the P-glycoprotein Efflux Pump in the Blood-Brain Barrier
BMJ 331:513, Troger,U.,et al, 2005

Underappreciated Statin-Induced Myopathic Weakness Causes Disability
Neurorehabil Neural Repair 19:259-263, Dobkin,B.H., 2005

Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004

Statin-Associated Myopathy
JAMA 289:1681-1690, Thompson,P.D.,et al, 2003

Clinicopath Conf., Colchicine Myoneuropathy
NEJM 349:1656-1663, Case 33-2003, 2003

AAC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Stroke 33:2337-2341, Pasternak,R.C.,et al, 2002

Statin-Associated Myopathy With Normal Creatine Kinase Levels
Ann Int Med 137:581-585,617, Phillips,P.S.,et al, 2002

Generalised Muscular Weakness after Botulinum Toxin Injections for Dystonia:A Report of Three Cases
JNNP 67:90-93, Bhatia,K.P.,et al, 1999

Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999

Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999

Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999

Intravenous Immune Globulin Therapy for Neurologic Diseases
Ann Int Med 126:721-730, Dalakas,M.C., 1997

Peripheral Neuropathy Secondary to Docetaxel (Taxotere)
Neurol 46:108-111, 21996., New,P.Z.,et al, 1996

Peripheral Neurotoxicity Induced by Docetaxel
Neurol 46:104-108, 21996., Hilkens,P.H.E.,et al, 1996

Development of General Weakness in a Patient with Amyotrophic Lateral Sclerosis after Focal Botulinum Toxin Injection
Neurol 46:845-846, Mezaki,T.,et al, 1996

Prolonged Paralysis After Neuromuscular Blockage
Muscle & Nerve, 18:937-94295., Gooch,J., 1995

Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994

Missed Neuroleptic Malignant Syndrome
BMJ 304:831-832, Renwick,D.S.,et al, 1992

Prolonged Weakness after Long-Term Infusion of Vecuronium Bromide
Ann Int Med 117:484-486, Kupfer,Y.,et al, 1992

Acute Quadriplegic Myopathy:A Complic of Treat with Steroids, Nondepolarizing Blocking Agents, or Both
Neurol 42:2082-2087, Hirano,M.,et al, 1992

Treatment of Hemifacial Spasm with Botulinum Toxin
Muscle & Nerve 15:1045-1049992., Yoshimura,D.M.,et al, 1992

Multistate Outbreak of Poisonings Associated with Illicit Use of Gamma Hydroxy Butyrate
JAMA 265:447-448, , 1991

Eosinophilia-Myalgia Syndrome, A Clinical Case Series of 21 Patients
Arch Int Med 151:533-537, Philen,R.M.,et al, 1991

Aggravation of Myasthenia Gravis by Erythromycin
J Pediatr 119:155-156, Absher,J.R.&Bale,J.F., 1991

Colchicine-Induced Myopathy and Neuropathy
Neurol 41:943, Younger,D.S.,et al, 1991

Complete Ophthalmoplegia as a Complication of Acute Corticosteroid-and Pancuronium-Associated Myopathy
Neurol 41:921-922, Sitwell,L.D.,et al, 1991

Clinical Use of Botulinum Toxin
National Institutes of Health Consensus Develop Conf Stmt, Nov 12-14, 1990, Arch Neurol 48:1294-1298, 199, 1991



Showing articles 0 to 50 of 226 Next >>